Neosoma, Inc., developer of a software medical device platform to help advance brain cancer care and clinical trials, announced the incorporation of a wholly-owned subsidiary in Bern, Switzerland: Neosoma GmbH.
In 2019, Neosoma established a close research and development collaboration with the University of Bern, centered around a long-term licensing agreement leveraging deep learning technology developed at the university’s ARTORG Center for Biomedical Engineering Research.
Since establishing a close research and development collaboration with the University of Bern and the ARTORG Center for Biomedical Engineering Research in 2019, the collaboration has grown. Incorporating a Neosoma subsidiary in Bern allows this research collaboration to deepen even further. As the main clinical partner, the Inselspital’s Department of Radiation Oncology (UKRO) was and continues to be involved in the creation of Neosoma’s Swiss subsidiary.
